AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

SerpinB3 Expression, PAR2 and SCCA-PD Polymorphism in Acute Respiratory Distress Syndrome

Recruitingn/aAges 18 Years - anyAllUniversity of Padova
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The Acute Respiratory Distress Syndrome (ARDS) is a systemic syndrome characterized by severe respiratory failure, inflammation, loss of aerated tissue and high mortality. Recently, significant efforts have been made to phenotype ARDS patients through a wide range of new biomarkers and imaging indices with the goal of developing personalized treatments based on patient's biophenotypization. Recent literature demonstrates, both in vitro and in vivo but not yet in ARDS patients, that the serine protease inhibitor(SERPIN)-B3 plays a crucial role in the pathological mechanism of pulmonary fibrogenesis, and, similarly, protease-activated receptors(PAR2) is highly involved in this aberrant inflammatory response. Consequently, studying the expression of SERPINB3 (including SCCA-PD polymorphism) and PAR2, in association with a detailed clinical and biomolecular phenotypization, could allow new

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * ARDS DIAGNOSIS * IMV Exclusion Criteria: * Age under 18 years * Pregnancy status * Lack of consent to participate in the study * Contraindications to fiberoptic bronchoscopy and/or BAL (bronchoalveolar lavage) * Patients with chronic inflammatory skin conditions * Patients with chronic lung diseases * Patients with inflammatory respiratory diseases * Patients with neoplasms such as: squamous cell carcinoma of the cervix, squamous cell carcinoma of the esophagus, lung adenocarcinoma, breast adenocarcinoma, pancreatic adenocarcinoma, hepatocellular carcinoma * History of active or passive smoking
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

1 site
Azienda Ospedaliera di Padova
Padova, Italy
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy